

Are platelets necessary in box 1 of a major haemorrhage pack for trauma?



**NICOLA CURRY
CONSULTANT HAEMATOLOGIST
OXFORD**

**SPOTLIGHT ON PLATELETS,
BIRMINGHAM NOVEMBER 2015**


Trauma haemorrhage in UK




- Trauma 30-40% patients deaths from haemorrhage

| | Incidence | Annual UK Cost | Annual UK mortality |
|--------|----------------|----------------|---------------------|
| Trauma | 13 per 100,000 | £168 million | ~10,000 |

24 hour mortality




30 day mortality



Why is haemostasis important?



- 25% trauma patients have coagulopathy
- Haemorrhagic deaths are often in first 6 hours
- Predictor of massive transfusion need
- Risk of death is x3-4 higher
- Cause of death:
 - Early: bleeding
 - Late: all other causes (MOF, ALI, etc)



PROPPR study



Research

Original Investigation

Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma The PROPPR Randomized Clinical Trial

John B. Holcomb, MD; Barbara C. Tilley, PhD; Sarah Baraniuk, PhD; Erin E. Fox, PhD; Charles E. Wade, PhD; Jeanette M. Podbielski, RN; Deborah J. del Junco, PhD; Karen J. Brasel, MD, MPH; Eileen M. Bulger, MD; Rachael A. Callcut, MD, MSPH; Mitchell Jay Cohen, MD; Bryan A. Cotton, MD, MPH; Timothy C. Fabian, MD; Kenji Inaba, MD; Jeffrey D. Kerby, MD, PhD; Peter Muskat, MD; Terence O'Keeffe, MBChB, MSPH; Sandro Rizoli, MD, PhD; Bryce R. H. Robinson, MD; Thomas M. Scalea, MD; Martin A. Schreiber, MS; Deborah M. Stein, MD; Jordan A. Weinberg, MD; Jeannie L. Callum, MD; John R. Hess, MD, MPH; Nena Matijevic, PhD; Christopher N. Miller, MD; Jean-Francois Pittet, MD; David B. Hoyt, MD; Gail D. Pearson, MD, ScD; Brian Leroux, PhD; Gerald van Belle, PhD; for the PROPPR Study Group

PROPPR study

- 12 level trauma centres in US
- 680 patients (338 vs. 342)
- Adults with trauma predicted to need a MT (10 or more RBC in 24h)
- Primary outcome: 24hr + 30 day mortality – powered to see a 10% difference




| | | Container 1 | Container 2 |
|-------------------------------|-----------|-------------|-------------|
| Group 1 ^a 1:1:1 | Platelets | 1 | 1 |
| | Plasma | 6 | 6 |
| | RBCs | 6 | 6 |
| Group 2 ^b 1:1:2 | Platelets | 0 | 1 |
| | Plasma | 3 | 3 |
| | RBCs | 6 | 6 |

^a Group 1: Platelets first, then alternate RBCs and Plasma, as clinically required.

^b Group 2: Platelets first (if available), then alternate 2 RBCs and 1 Plasma, as clinically required.

The container cycles were repeated until hemostasis was achieved and resuscitation completed.

PROPPR



No differences between overall 24h (12.7% vs. 17%) and 30 day mortality (22.4% vs. 26.1%)

Reduction in death from exsanguination: 9.2% vs. 14.6% ($p = 0.03$)

PROPPR



- More patients achieved anatomic haemostasis:
 - 86.1% vs. 78.1% ($p = 0.006$)
- Median no. blood components given during 1st haemorrhage:
 - 16units vs. 15 units
- There were no differences in ARDS, MOF, VTE and transfusion events

What evidence did the PROPPR team have prior to study start?



FFP:RBC RATIOS

PLT:RBC RATIOS

Evidence for FFP:RBC ratios

| Study (2007-2011) | N | % blunt | MT definition | Coagulation Pre | Coagulation Post | Ratio ↓ mortality |
|-------------------|-----|---------|---------------|-----------------|------------------|-------------------|
| Borgman | 246 | 6 | ≥10U/24 hr | INR 1.63 | NR | 1:1.4 |
| Duschesne | 135 | 42 | ≥10U/24 hr | NR | NR | 1:1 |
| Gunter | 259 | 46 | >10U/24 hr | NR | NR | >2:3 |
| Holcomb | 466 | 65 | ≥10U/24 hr | INR 1.6 | NR | 1:2 |
| Kashuk | 133 | NR | >10U/6 hr | INR 1.4 | Max ↓ 1:1- 1:2 | 1:2-1:3 |
| Maegele | 713 | 92 | >10U by ITU | APTT 53s | NR | 1:1 |
| Scalea | 250 | 85 | ≥10U/24 hr | NR | NR | No |
| Sperry | 415 | 100 | >8U/12 hr | INR 1.82 | NR | ≥1:1.5 |
| Snyder | 134 | 40 | ≥10U/24 hr | INR 1.6-1.9 | NR | No |
| Teixeira | 383 | NR | ≥10U/24 hr | NR | NR | ≥1:3 |
| Zink | 466 | 65 | ≥10U/24 hr | INR 1.3-1.5 | NR | ≥1:1 |
| Shaz | 214 | 54 | >10U/24 hr | NR | NR | ≥1:2 |
| Davenport | 50 | 88 | ≥10U/24 hr | PT 12 | Max ↓ 1:2-3:4 | N/A |
| Magnotti | 103 | 63 | ≥10U/24 hr | INR 1.6-2.4 | NR | No |


Evidence for plt:RBC ratios

| Study | n | setting | Plt count | Other blood products used | Author statement |
|---------------------------|------|------------------------|-----------|---------------------------|--|
| Holcomb, 2011 | 643 | Civilian, MT | 192-216 | FFP, rVIIa | NS difference |
| Sambasivan, 2011 | 1181 | Civilian, non-MT | 198-245 | FFP | NS difference |
| Perkins, 2009 | 464 | Military, MT | 255-261 | FFP, cryo, rVIIa | Improved mortality |
| Inaba, 2010 | 657 | Civilian, MT | NR | FFP, cryo | Improved mortality |
| Shaz, 2010 | 216 | Civilian, MT | NR | FFP | Improved mortality |
| *Dirks, 2010 | 253 | Civilian, all bleeding | 186-190 | FFP | NR |
| *Cotton, 2008 | 211 | Civilian, MT | NR | FFP | NS difference |
| *Del Junco, 2013 (PROMMT) | 619 | Civilian, MT | NR | FFP | Insufficient data to show early plts improve mortality, Most pts had plts tx after 3 hours (see UK data) |

* - minimal survival bias


Hallet et al, Crit Care Med 2013


Outcomes according to survival bias



UK NIHR Trauma study

- 22 hospitals, between 2009-2011
 - Major trauma centres & trauma units
- N = 12,290
 - 479 major transfusions
 - 146 massive transfusions
- Median times to first Tx:
 - RBC – 43 mins (30 mins)
 - FFP – 93 mins (80 mins)
 - **Plts – 144 mins (120 mins)**
 - Cryo - 184 mins (156 mins)
- **19.2% pts with MT did not get any plts in first 24 h**
- Mortality: 16% at 24h, 25% at 28 d, 32% at 1 year








> 50% of deaths occur in first 3 hrs, with < 10% after 10 h

Platelet POC tests

- Platelet mapping/
Multiplate:
 - Several studies: reduced ADP activated platelet function
 - Correlates with transfusion need
- Solomon *et al*, 2011:
 - Multiplate: ADP reduced in non-survivors
 - ROTEM: platelet component ↓



Platelet testing



How to determine if platelets should be given?

‘Plt contribution’ to the MA/MCF as well as the speed of development of a stable clot

Platelet role in TIC



Kutcher et al:

- 101 trauma patients
- Impedance aggregometry to characterise platelet dysfunction in trauma patients on arrival to ED
- 45.5% showed decreased platelet aggregation in response to:
 - ADP, thrombin receptor-activating peptide, arachidonic acid (AA), and/or collagen.
- 10-fold increase in mortality in patients having any one of these platelet aggregation deficits
- Admission AA and collagen responsiveness were sensitive and specific predictors of mortality.

Solomon et al:

- 163 trauma patients
- Multiple electrode aggregometry testing showed minor changes in plt response were associated with mortality (reduction in ADP response found in non-survivors)
- The platelet contribution to clot firmness using (ROTEM) was significantly decreased in nonsurvivors

Wohlauer et al:

- Platelet Mapping: found a pronounced inhibition of clot strength when activated with ADP and AA in 51 trauma patients sampled within 30 minutes of injury

Kutcher et al, *J Trauma Acute Care Surg* 2012; 73: 13-9.
Solomon et al, *Thromb Haemost* 2011; 106: 322-30.
Wohlauer et al, *J Am Coll Surg* 2012; 21: 739-46.

VHA Guiding treatment



| Reference | Study Type | No | TEG or ROTEM | Treatment Algorithm | Outcomes |
|----------------|--|--------------|--------------|--|--|
| Johansson 2009 | Retrospective cohort, historical control | 442 390 | TEG | $\uparrow R$ - FFP $\alpha < 52$ – FFP or Fg MA < 46 – plts Ly30 > 8% - TA | DCR + TEG improved survival by 11% |
| Kashuk 2011 | Prospective Historical control | 34 34 | r-TEG | G < 5.0 and: $\uparrow R > 110$ sec - FFP $\alpha < 66$ – cryo MA < 54 - plts | Mortality fell from 65 % to 29% Conducting an RCT |
| Schochl 2010 | Retrospective | 131 | ROTEM | FgC: if FIBTEM MCF < 10mm PCC: if EXTEM CT > 1.5x ULN | Signif. reduction in mortality compared to expected mortality (p=0.03) |
| Schochl 2011 | Retrospective 2 databases | 80 | ROTEM | As above | Reduction of blood exposure |
| | | 601 | | Nil | No difference in death |

iTACTIC trial



- **Since platelet count is slow to fall**
 - CCT/FBC do not differentiate platelet dysfunction
 - Might POC testing provide a better means of guiding transfusion when compared to CCT
- **Large European RCT in 6 major trauma centres**
- **Aiming: 392 patients**
- **Primary endpoint: proportion of subjects alive and free from MT at 24h**
- **Powered to see a 13% reduction in primary outcome in VHA group**

iTACTIC trial



- **1:1:1** - 1 RBC : 1 FFP/Octaplas : 1 Platelets
- **TXA** - 1g iv + 1g iv 8 hours infusion, if < 3 hours post injury.
- If 1g administered prehospital, add 1g iv 8 hours infusion


CCT arm Algorithm



If lab INR/poc INR > 1.2
Give 4 units FFP/Octaplas



If Fibrinogen < 1.5 g/L
Give 2 pool Cryo OR 4 gm Fibrinogen concentrate
If Fibrinogen < 1.0 g/L
Give 3 pools Cryo OR 6 gm Fibrinogen concentrate




If platelet count < $100 \times 10^9/L$
Give 1 pool platelets

VHA Algorithm ROTEM®



If FIBTEM CA5 < 10mm
Give 2 pools Cryo OR 4 gm Fibrinogen concentrate
If FIBTEM CA5 < 10mm AND EXTEM CA5 < 30mm
Give 3 pools Cryo OR 6 gm Fibrinogen concentrate



If EXTEM CA5 < 40mm AND FIBTEM CA5 > 10mm
Give 1 pool platelets



If EXTEM CT > 80 secs
Give 4 units FFP/Octaplas



If EXTEM Li30 < 97%
Give 1gm TXA

Is there an alternative?

- Fibrinogen is a key coagulation protein
- Low Fg levels are associated with poorer outcomes
- NHSBT has led the way in trauma Fg replacement trials
- CRYOSTAT
- E-FIT

CRYOSTAT
EARLY CRYOPRECIPITATE IN TRAUMA



Acknowledgements



- Dr. S. Stanworth
- Prof. K. Brohi
- NHSBT CTU
- Royal London Trauma Sciences
- INTRN



- NIHR
- NHSBT
- John Radcliffe ED Dept.
- Oxford Haemophilia & Thrombosis Centre

